聯邦制藥(03933.HK)2020年純利升9.5%至7.03億元 末期息8分
格隆匯3月31日丨聯邦制藥(03933.HK)公佈2020年度業績，期內集團實現收入87.72億元人民幣(單位下同)，同比增長4.5%；EBITDA為16.78億元，同比下降6.7%；除税前溢利8.82億元，同比增長4.8%；公司擁有人應占溢利7.03億元，同比增長9.5%；每股基本盈利39.81分，宣派末期股息每股8分。
2020年度，中間體產品、原料藥及製劑產品的分部收入(包括分部間的銷售)分別較去年上升1.1%、2.1%及5.8%。中間體產品及製劑產品的分部業績分別較去年上升195.5%及13.2%。原料藥的分部業績較去年下跌10.1%。
集團持續致力於藥品研發，並穩步推進在研產品專案，2020年度投放於研發費用約3.40億元。現時開發中的新產品達26項，其中1類新藥10項。
生物研發方面，集團重點佈局糖尿病藥物開發，項目覆蓋門冬胰島素注射液、德谷胰島素注射液、利拉魯肽注射液、德谷門冬雙胰島素混合注射液、德谷胰島素利拉魯肽混合注射液等多個品種。基於日趨完善的生物研發平台，集團將繼續拓展於內分泌及自身免疫疾病等領域的相關產品佈局。此外，單抗實驗室於年內正式投入使用，標誌着集團生物大分子藥物平台建設取得重點進展。
化藥研發方面，眼科、皮膚科用藥等多個品種正在推進，注射劑一致性評價也在同步開展。創新藥研發方面，用於治療中度至重度活動性類風濕性關節炎的1類新藥WXSH0150於年內獲批臨牀。未來，集團將繼續向新藥領域邁進。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
